FierceBiotech4d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
BAIYU Holdings Touches 52-Week Low in Return to Nasdaq After September SEC Halt
BAIYU Holdings shares touched a 52-week low as the stock returned to Nasdaq, over a month after the Securities and Exchange Commission temporarily suspended trading. However, shares could possibly ...
ENDPOINTS NEWS4d
No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...
The Pharma Letter4d
Chengdu Baiyu enters into a license deal with Novartis
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...
Asia One13d
BAIYU Holdings Files Nasdaq Delisting Appeal Notice and Advances Recently Announced Projects
BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply ...
Nasdaq Resumes Trading in BAIYU Holdings, Inc.
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading will resume in BAIYU Holdings, Inc. (Nasdaq: BYU) at 9:00 a.m. Eastern Time on October 9, ...
PipelineReview.com3d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
Morningstar13d
Nasdaq Resumes Trading in BAIYU Holdings, Inc.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...